Relation of mitochondrial oxygen consumption in peripheral blood mononuclear cells to vascular function in type 2 diabetes mellitus

Abstract

Recent studies have shown mitochondrial dysfunction and increased production of reactive oxygen species in peripheral blood mononuclear cells (PBMCs) and endothelial cells from patients with diabetes mellitus. Mitochondria oxygen consumption is coupled to adenosine triphosphate (ATP) production and also occurs in an uncoupled fashion during formation of reactive oxygen species by components of the electron transport chain and other enzymatic sites. We therefore hypothesized that diabetes would be associated with higher total and uncoupled oxygen consumption in PBMCs that would correlate with endothelial dysfunction. We developed a method to measure oxygen consumption in freshly isolated PBMCs and applied it to 26 patients with type 2 diabetes mellitus and 28 non-diabetic controls. Basal (192±47 vs 161±44 pmoles/min, p=0.01), uncoupled (64±16 vs 53±13 pmoles/min, p=0.007), and maximal (795±87 vs 715±128 pmoles/min, p=0.01) oxygen consumption rates were higher in diabetic patients compared to controls. There were no significant correlations between oxygen consumption rates and endothelium-dependent flow-mediated dilation measured by vascular ultrasound. Non-endothelium-dependent nitroglycerin-mediated dilation was lower in diabetics (10.1±6.6 vs 15.8±4.8%, p=0.03) and correlated with maximal oxygen consumption (r = −0.64, p=0.001). In summary, we found that diabetes mellitus is associated with a pattern of mitochondrial oxygen consumption consistent with higher production of reactive oxygen species. The correlation between oxygen consumption and nitroglycerin-mediated dilation may suggest a link between mitochondrial dysfunction and vascular smooth muscle cell dysfunction that merits further study. Finally, the described method may have utility for the assessment of mitochondrial function in larger scale observational and interventional studies in humans.

Keywords

blood mononuclear cells diabetes mellitus mitochondria oxygen consumption

Introduction

In addition to generating adenosine triphosphate (ATP) via oxidative phosphorylation, mitochondria are important for many other aspects of cellular function, including calcium flux, apoptosis, and intracellular signaling.¹ It is now recognized that altered mitochondrial function contributes to the aging process and many common disease states, including neurodegenerative diseases, cancer, and atherosclerosis.^2–5 In light of the ongoing obesity epidemic, there is also considerable interest in mitochondrial dysfunction in the pathogenesis of type 2 diabetes mellitus and its vascular complications.^6–11 Recent work has demonstrated increased mitochondrial production of reactive oxygen species (ROS), oxidative stress, and altered mitochondrial morphology and dynamics in peripheral blood mononuclear cells and endothelial cells from patients with diabetes mellitus.^12–15

Cellular oxygen consumption is increasingly recognized as a fundamental measure of mitochondrial function.^16–18 The basal oxygen consumption rate reflects coupled mitochondrial respiration as well as uncoupled consumption of oxygen to form ROS at mitochondrial and non-mitochondrial enzymatic sites. Coupled and uncoupled respiration can be distinguished by examining the effects of an inhibitor of ATP synthase (oligomycin) and/or complex III (antimycin A). The maximal oxygen consumption rate, provoked by the addition of a mitochondrial uncoupling agent such as carbonyl cyanide p -trifluoromethoxyphenylhydrazone (FCCP), provides an index of energetic reserve capacity. The Clark oxygen electrode¹⁹ and the Seahorse extracellular flux analyzer^16,17 can be used to measure oxygen consumption rates in cell suspensions and adherent cells in tissue culture, respectively. These approaches have provided insight into the importance of mitochondrial dysfunction in experimental models of disease.

Study of mitochondrial respiration in humans has previously been limited by a number of technical issues. The Clark electrode has been used to examine oxygen consumption in human leukocytes in suspension,^20,21 but its requires a relatively large volume of blood. Attempts to measure oxygen consumption in blood cells using the Seahorse device have been limited by displacement of non-adherent cells during the automated movement of the oxygen sensor. For the present study, we developed a method to immobilize readily available peripheral blood mononuclear cells (PBMCs) that allows us to measure mitochondrial oxygen consumption with the Seahorse XF96 analyzer (Seahorse Bioscience, North Billerica, MA, USA). We used the method to measure mitochondrial function in patients with type 2 diabetes mellitus and non-diabetic controls and related the results to vascular function. Prior studies have shown increased mitochondrial production of ROS in PBMCs, endothelial cells, and other cell types in diabetes, suggesting systemic mitochondrial dysfunction.^12,13,22 On this basis, we hypothesized that diabetes mellitus would be associated with higher total and uncoupled oxygen consumption that would correlate with endothelial dysfunction, providing evidence in humans that mitochondrial dysfunction might be relevant to cardiovascular disease in humans.

Materials and methods

Study subjects

Adult patients with type 2 diabetes mellitus and healthy volunteers were recruited at Boston Medical Center by advertisement. Diabetes was defined as fasting glucose ≥126 mg/dl or ongoing treatment for type 2 diabetes mellitus. Healthy volunteers were taking no medications, had a fasting glucose <100 mg/dl, and had never smoked or had stopped smoking for at least a year prior to enrollment. A fasting blood sample was obtained in the morning by venipuncture, and glucose and lipids were measured in the Boston Medical Center Clinical Laboratory. Non-invasive measurement of endothelium and non-endothelium-dependent vasodilator function was then completed, as described below. The study protocol was approved by the Boston Medical Center Institutional Review Board and all participants provided written informed consent.

Materials and reagents

The study used the following materials and reagents: FCCP (Sigma Life Science, St Louis, MO, USA), oligomycin (Sigma Life Science), poly-d-lysine (EMD Millipore, Billerica, MA, USA), Hanks’ balanced salt solution (HBSS) (Life Technologies, Gibco, Grand Island, NY, USA), Dulbecco’s modified eagle medium (DMEM) (Seahorse Bioscience), glucose (American Bioanalytical, Natick, MA, USA), etomoxir (Calbiochem-EMD Biosciences, Billerica, MA, USA), and sodium pyruvate (Life Technologies, Gibco).

Isolation of PBMCs

Venous blood was collected into commercially available cell preparation tubes for PBMCs (BD Vacutainer CPT with sodium citrate; Becton, Dickinson and Company, Franklin, NJ, USA). The tubes were spun at 1650 g for 30 minutes at room temperature and cell layers were collected and transferred into 25 mL of HBSS. This solution was centrifuged for an additional 10 minutes at 250 g at room temperature. The pellet was resuspended in 15 mL of fresh HBSS and the cell count was determined using a glass hemocytometer (Double Neubauer Counting Chamber; Hausser Scientific, Horsham, PA, USA). Fluorescence activated cell sorting (FACS) analysis in the Boston Medical Center Hematology Laboratory of samples from five subjects demonstrated that this isolation method yielded a cell population of 82±4% lymphocytes (CD3 positive cells) and 14±2% monocytes (CD14 positive cells), with the remaining 4% comprised of other mononuclear cells.

Plate preparation

Prior to the addition of PBMCs, XF96 plates (Seahorse Bioscience) were treated with poly-d-lysine to improve cell adherence. Poly-d-lysine 50 µg/mL was prepared in sterile water and 30 µL was added to each well for 1 hour. The solution was removed, the wells were washed with 300 µL sterile water, and the plate was dried in a laminar flow hood for 30 minutes.

PBMCs were suspended in DMEM supplemented with pyruvate 1.0 mM and glucose 5.5 mM. The DMEM was warmed to 37°C and the pH was adjusted to 7.4 prior to cell suspension. PBMCs (600,000 per well) were seeded onto poly-d-lysine-treated XF96 microplates (Seahorse Bioscience). After seeding, the plates were spun with slow acceleration (4 on a scale of 9) to a maximum of 450 rpm and then allowed to stop with zero braking (Model 5810R Centrifuge; Eppendorf North America, Hauppauge, NY, USA). The plate orientation was reversed and the plate was spun again to 650 rpm in the same fashion. Plates were maintained at 37°C for approximately 20 minutes prior to loading during XF96 analyzer calibration. During development of the method, we visualized the distribution of PBMCs in XF96 wells after plate preparation using an inverted microscope. PBMCs were evenly distributed in a single layer with approximately 89% confluence. For each subject, we confirmed the viability of cells by trypan blue exclusion prior to measurement of oxygen consumption.

Oxygen consumption measurement protocol

Oxygen consumption rates were measured in accordance with manufacturer instructions (Seahorse Bioscience). The assay media (DMEM) was supplemented with glucose (5.5 mM) and pyruvate (1 mM) and the pH was adjusted to 7.4. In preliminary studies testing 200,000 to 1 million cells per well, we found an optimal signal and uniform distribution of cells on the bottom of the well with the use of 600,000 cells per well. Experiments were replicated in six wells and averaged for each experimental condition. The average coefficient of variation for the basal oxygen consumption rate was 6.4±2.0%.

Oxygen consumption measurements were made approximately every 8 minutes under basal conditions, after the addition of a saturating concentration of oligomycin (5 µmoles/L),²³ and after the addition of FCCP (1 µmoles/L). Basal and post-oligomycin respiration rates were calculated by averaging the last four measurements after achieving a steady state. Coupled respiration was expressed as the percent decrease from basal respiration. Maximal FCCP respiration was taken as the highest measurement after the addition of FCCP.

Assessment of vascular function

We used vascular ultrasound to measure endothelium-dependent flow-mediated dilation of the brachial artery as previously described.²⁴ Subjects fasted and withheld all medications on the morning of study. Two-dimensional ultrasound images of the brachial artery were recorded before and 1 minute after induction of reactive hyperemia by 5-minute cuff occlusion of the upper arm. We measured Doppler flow velocity at baseline and immediately after cuff release. Non-endothelium-dependent dilation of the brachial artery was assessed by examining the change in brachial diameter induced by sublingual nitroglycerin (0.4 mg). The nitroglycerin portion of the vascular testing protocol was omitted if the participant had systolic blood pressure less than 100 mmHg or had a history of migraine headaches or nitrate intolerance.

Statistical analyses

Clinical characteristics of the diabetic and healthy control groups were compared using the unpaired t-test or chi-squared test for continuous and categorical variables respectively. Group differences (controls versus diabetic patients) in oxygen consumption were compared using the Wilcoxon signed rank test because examination of histograms suggested that these variables lacked a normal distribution. Linear regression analysis was used to determine the relation between log-transformed oxygen consumption rates and diabetes mellitus while adjusting for age, sex, and black race. Changes in oxygen consumption over time according to group (controls and diabetic patients) were assessed using analysis of variance for repeated measures after log transformation of the oxygen consumption variables. We calculated Spearman’s correlation coefficients to test the relation between vascular function variables and oxygen consumption rates. P<0.05 was considered to be statistically significant. Data are expressed as mean±SEM. Statistical analyses were completed using SPSS Version 20 (IBM, Inc.).

Results

Study subjects

We enrolled 54 subjects (26 with diabetes mellitus and 28 controls). Their clinical characteristics are shown in Table 1. The two groups were similar in age and sex. As expected, the patients with diabetes mellitus had higher fasting glucose and body mass index, lower high-density lipoprotein (HDL) cholesterol, and a trend toward higher triglyceride levels (p=0.05). Total and low-density lipoprotein (LDL) cholesterol levels were lower in diabetic patients, likely reflecting the ongoing treatment with cholesterol-lowering drugs. Also as expected, diabetic patients were taking drugs to lower blood glucose and blood pressure (Table 1).

Table 1.

Clinical characteristics.

	Controlsn=28	Diabetes mellitusn=26
Age, years	52 ± 11	56 ± 9
Sex, female, n (%)	13 (46%)	16 (62%)
Black race, n (%)	9 (32%)	15 (58%)
Glucose, mg/dl	90 ± 11	134 ± 70*
Total cholesterol, mg/dl	200 ± 30	164 ± 35*
HDL cholesterol, mg/dl	59 ± 17	45 ± 11*
LDL cholesterol, mg/dl	122 ± 24	92 ± 28*
Triglyceride, mg/dl	98 ± 61	136 ± 77
BMI, kg/m²	25.7 ± 2.6	33.3 ± 8.0*
Systolic blood pressure, mmHg	125 ± 11	131 ± 17
Diastolic blood pressure, mmHg	75 ± 7	72 ± 13
Statin therapy, n (%)	0	10 (38%)*
ACE/ARB therapy, n (%)	0	17 (65%)*
Metformin therapy, n (%)	0	17 (65%)*
Insulin therapy, n (%)	0	15 (58%)*

Data are mean ± SD.

p<0.05 versus control group.

HDL, high-density lipoprotein; LDL, low-density lipoprotein; BMI, body mass index; ACE/ARB, angiotensin converting enzyme inhibitor/angiotensin receptor blocker.

Oxygen consumption rates in controls and diabetic patients

Table 2 displays oxygen consumption rates in PBMCs from controls and diabetic patients. As shown, basal, post-oligomycin (uncoupled), and maximal after FCCP oxygen consumption rates were all higher in diabetic patients compared to controls. Interestingly, coupled respiration, calculated as the percent decrease after oligomycin, did not differ between groups. These findings are consistent with our hypothesis that diabetes would be associated with higher uncoupled respiration due to higher production of ROS. The sequence of reagents and time course of oxygen consumption measurements is displayed in Figure 1. As shown, oxygen consumption was consistently higher in diabetic patients.

Table 2.

Diabetes mellitus and oxygen consumption rates in PBMCs.

	Control (n=28)	Diabetes mellitus (n=26)	p-value
Basal OCR, pmoles/min	161 ± 44	192 ± 47	0.01
OCR after oligomycin, pmoles/min	53 ± 13	64 ± 16	0.007
Coupled respiration, % decrease	67 ± 3%	66 ± 4%	0.73
Maximal OCR, pmoles/min	715 ± 128	795 ± 87	0.01

Data are mean ± SD.

PBMCs, peripheral blood mononuclear cells; OCR, oxygen consumption rate.

Figure 1.

Oxygen consumption rates (OCR) in peripheral blood mononuclear cells (PBMCs) from control subjects (n=28) and patients with type 2 diabetes mellitus (n=26). The OCR was measured approximately every 8 minutes using an XF96 analyzer as described in Methods. Basal and post-oligomycin (5 µmoles/L) rates were calculated by averaging the last four measurements after achieving a steady state. Sequential measurements were also made after the addition of carbonyl cyanide p-trifluoromethoxyphenylhydrazone (FCCP) (1 µmoles/L), which depolarizes the mitochondrial membrane and induces maximal oxygen consumption. As shown, oxygen consumption rates were higher in PBMCs from diabetic patients (p=0.01 for diabetes main effect and p=0.03 for diabetes by time interaction by repeated measures ANOVA).

Other clinical correlates of oxygen consumption rates

We noted that there were non-significant tendencies for higher age (p=0.13), more females (p=0.27), and more black participants (p=0.06) in the diabetic group (Table 1), although none of these clinical characteristics correlated with oxygen consumption rates. As shown in Table 3, diabetes mellitus was associated with significantly higher basal, post-oligomycin, and maximal oxygen consumption rates in multivariable models adjusting for age, sex, and black race, suggesting that confounding effects of these factors do not explain our findings.

Table 3.

Age, sex, and race-adjusted relations between diabetes mellitus and oxygen consumption rates.

	Diabetes mellitus
	β (SE)	p
Basal, pmoles/min	30 (14)	0.02
After oligomycin, pmoles/min	10 (4)	0.03
Coupled, % decrease	0.4 (0.1)	0.75
Maximal, pmoles/min	96 (32)	0.01

As shown in Table 1, some of the diabetic subjects were taking a statin, angiotensin converting enzyme inhibitor/angiotensin receptor blocker (ACEI/ARB), metformin, or insulin. We compared basal, post-oligomycin, maximal, and coupled oxygen consumption rates according to medication status among the diabetic subjects. Diabetic patients taking insulin had slightly higher coupled respiration (68±4%, n=15) compared to diabetics not taking insulin (64±3%, n=11; p=0.04), possibly suggesting that insulin treatment promotes mitochondrial respiration. Insulin treatment did not relate to the other measures of oxygen consumption (data not shown). Oxygen consumption rates also did not differ in diabetic patients who were and were not taking a statin, ACEI/ARB, or metformin (data not shown).

We explored the other clinical correlates of oxygen consumption in the whole cohort. We observed no relation between basal, post-oligomycin, post FCCP, or coupled respiration with age, sex, blood glucose, blood lipids, body mass index, or blood pressure (data not shown).

Dependence of oxygen consumption rates on fatty acid transport

Type 2 diabetes mellitus is associated with insulin resistance and decreased expression of glucose transporters that might limit entry of glucose into PBMCs.²⁵ As shown in Table 1, we observed a strong trend toward higher serum triglycerides in our participants (p=0.05). A decrease in glucose transport and higher triglycerides would both be expected to cause a shift away from glucose and toward fatty acids as a source of fuel in mitochondria. We therefore investigated whether differences in fatty acid utilization might account for the higher oxygen consumption rate observed in our diabetic subjects. As shown in Figure 2, inhibiting fatty acid transport into mitochondria with the carnitine O-palmitoyltransferase-1 (CPT-1) inhibitor etomoxir produced a dose-dependent decrease in basal oxygen consumption that did not differ between control and diabetic subjects. This result argues against a disproportionate dependence on fatty acid oxidation in PBMCs in diabetes mellitus.

Figure 2.

Etomoxir reduces the basal oxygen consumption rate (OCR) to an equivalent extent in diabetic patients and controls. The oxygen consumption rate was measured in peripheral blood mononuclear cells (PBMCs) incubated with the indicated concentrations of etomoxir as described in Methods. As shown, inhibiting fatty acid uptake produced a dose-dependent decrease in oxygen consumption (p<0.001) in both diabetic (n=5) and control subjects (n=5), but the response did not differ between groups (p=0.64 by analysis of variance for repeated measures).

Relation of oxygen consumption rates to vascular function

Table 4 displays vasodilator function in the control and diabetic subjects. As shown, endothelium-dependent flow-mediated dilation was lower in the diabetic subjects, whether expressed as percent change or absolute change (mm). Non-endothelium-dependent dilation of the brachial artery in response to sublingual nitroglycerin was also lower in the diabetic subjects. Finally, we observed a non-significant trend for lower reactive hyperemia, a measure of microvascular function, in the diabetic subjects. Since reactive hyperemia is the stimulus for flow-mediated dilation, reduced hyperemia might have accounted for our finding that flow-mediated dilation was lower in the diabetic subjects. However, diabetics had lower flow-mediated dilation after adjustment for reactive hyperemia, arguing against this possibility and providing additional evidence for impaired conduit artery endothelial dysfunction in the diabetic subjects.^26,27

Table 4.

Diabetes mellitus and vascular function.

	Controls (n=22)	Diabetes mellitus (n=21)	p-value
FMD, %	9.9 ± 5.3	6.1 ± 4.5	0.01
FMD, mm	0.41 ± 0.19	0.26 ± 0.17	0.01
Baseline diameter, mm	4.25 ± 0.58	4.57 ± 0.76	0.12
Nitroglycerin-mediated dilation, %	15.8 ± 4.8	10.1 ± 6.6	0.03
Hyperemic flow velocity, cm/sec	120 ± 25	108 ± 24	0.12
FMD/hyperemic velocity, 100*sec/cm	8.9 ± 5.3	5.8 ± 3.6	0.04

Data are mean ± SD.

FMD, flow-mediated dilation.

We investigated the relationships between oxygen consumption rates and vascular function. There were no significant correlations between brachial artery flow-mediated dilation (Figure 3, lower panel), hyperemic flow velocity, baseline diameter, and the measures of oxygen consumption (data not shown). Interestingly, there was a strong inverse correlation between nitroglycerin-mediated dilation and peak oxygen consumption rate (Figure 3, upper panel).

Figure 3.

Peak oxygen consumption in PBMCs correlates with nitroglycerin-mediated dilation (upper panel), but not flow-mediated dilation (lower panel).

Discussion

In this study, we developed a method that allowed for measurement of mitochondrial oxygen consumption in PBMCs and related the findings to vascular function in patients with type 2 diabetes mellitus. We observed higher basal, uncoupled, and maximal oxygen consumption in the diabetic group, findings consistent with our hypothesis that increased production of reactive species in diabetes mellitus would lead to an increase in uncoupled respiration. Inhibiting fatty acid transport into mitochondria with etomoxir lowered oxygen consumption to a similar extent in the two groups, suggesting that a shift toward fatty acid utilization does not explain our findings. Contrary to our initial hypothesis, we observed no significant correlation between measures of endothelial vasodilator function and oxygen consumption. There was a significant correlation between nitroglycerin-mediated dilation and maximal oxygen consumption in PBMCs, raising the possibility that mitochondrial function and respiratory reserve might relate to the function of vascular smooth muscle cells. Overall, the study provides evidence that diabetes mellitus is associated with increased uncoupled and maximal respiration in PBMCs that might be relevant to inflammation, altered immune function, and cardiovascular disease.

Our described method offers several advantages over other methods for assessing mitochondrial function in human subjects. Although the Clark electrode can be used to measure oxygen consumption rate in blood cells in suspension, the presented method uses fewer cells (6×10⁵ vs 10⁷), reflecting the greater sensitivity of the Seahorse device.^20,21,28 Other approaches for measuring mitochondrial function in humans have included measurement of mitochondrial enzyme activity in biopsied tissue and by magnetic resonance spectroscopy.^29,30 Such studies are invasive or require expensive equipment, and are poorly suited to the larger-scale epidemiological or intervention studies that would be required to understand how mitochondrial function relates to disease risk or management.

Prior studies have shown that mitochondrial function is relevant to leukocyte function. For example, mitochondrial membrane hyperpolarization and the production of ROS contribute to immune activation of monocytes and lymphocytes.^31,32 Maturation of memory T cells involves mitochondrial biogenesis and an increase in mitochondrial reserve capacity.³³ Several prior studies used a Clark electrode to examine oxygen consumption in PBMCs. Belikova and colleagues demonstrated higher and more uncoupled oxygen consumption in patients with sepsis.²⁰ Kuhnke and colleagues showed that patients with rheumatologic disease have higher basal oxygen consumption rates that correlate with activity of disease, increase with mitogenic stimulation, and decrease following steroid treatment.²¹ It is possible that systemic inflammation and activation of PBMCs in diabetes mellitus might relate to increased oxygen consumption in the present study. It is important to acknowledge that we assessed quiescent cells and a mixed population of lymphocytes and monocytes in the present study. As has recently been emphasized, it would be interesting to examine activated cells and to compare results in monocyte and lymphocyte subsets to gain further insight into the importance of mitochondrial function for leukocyte biology.³⁴

Several prior studies specifically measured mitochondrial function in other types of blood cells from patients with diabetes mellitus. Hernandez-Mijares and colleagues reported lower oxygen consumption rates measured by a Clark electrode in neutrophils from diabetic patients.³⁵ Avila and colleagues reported lower oxygen consumption rates in platelets from diabetic patients measured with the Seahorse XF24 analyzer.³⁶ In that study, Cell-Tak (BD Biosciences (San Jose, CA) was used to enhance platelet adherence to the wells. Cell-Tak was also used in a very recent report examining oxygen consumption rates in human leukocytes and platelets³⁴ and appears to be a reasonable alternative to poly-d-lysine, which was used in our study.

We previously reported higher mitochondrial ROS production, higher membrane potential, a shift toward mitochondrial fission, and lower mitochondrial mass in PBMCs that were isolated from diabetic patients by the method used in the present study.¹² Our new findings add to that prior work and provide additional evidence for altered mitochondrial function in diabetes using an emerging and potentially more clinically relevant approach. Higher ROS production likely accounts for the higher basal, post-oligomycin, and maximal oxygen consumption rates observed in the present study. It is a limitation of our study that we were not able to simultaneously measure ROS production and oxygen consumption rates to investigate this hypothesis. It is notable that we observed higher oxygen consumption despite our prior finding of lower mitochondrial mass. Studies with isolated mitochondria will be needed to differentiate the relative importance of mitochondrial mass, energy demand, coupled respiration, and ROS production for net cellular oxygen consumption in diabetes mellitus. In regard to mechanism, our finding that a CPT-1 inhibitor had similar effects in cells from both groups argues against an alteration in fatty acid utilization. Further study will be required to elucidate the mechanisms accounting for higher oxygen consumption and other mitochondrial abnormalities in diabetes mellitus. Overall, these studies in PBMCs are consistent with a large body of work suggesting altered mitochondrial respiratory capacity and function in other tissues, including skeletal muscle, liver, islet cells, and myocardium in diabetes.^8,30,37 Since they are readily available, oxygen consumption in PBMCs may be a useful endpoint to study cross-sectional correlates and the effects of interventions on mitochondrial function in systemic diseases, such as type 2 diabetes mellitus.

Our study also adds to the prior literature by examining the relationship between oxygen consumption in circulating PBMCs and vascular function. We observed that patients with diabetes mellitus had markedly impaired vasodilator function of the conduit brachial artery and a trend toward blunted reactive hyperemia, findings that are consistent with many prior studies (see Tabit et al. for a review).²² Despite the apparent systemic nature of mitochondrial dysfunction in diabetes and a large body of experimental work implicating these mechanisms in endothelial dysfunction,⁵ we found no significant correlation between oxygen consumption rates in PBMCs and endothelial function. We did observe a significant correlation between maximal oxygen consumption and non-endothelium-dependent nitroglycerin-mediated dilation. It is known that mitochondrial ROS contribute to dysfunction of vascular smooth muscle cells in cardiovascular disease.³⁸ One might speculate that common mechanisms might account for altered oxygen consumption rates in PBMCs and vascular smooth muscle cells in diabetes, but investigation of this possibility goes far beyond the scope of the present study. A more likely explanation for the lack of correlation between oxygen consumption rates and endothelial function is the relatively high degree of variability associated with non-invasive vascular function measurements and the relatively modest sample size. Finally, these results emphasize the importance of direct examination of endothelial cells to understand mechanisms of endothelial dysfunction, and it is notable that such studies are now feasible in humans.^13,15

Our study has a number of limitations. First, the sample size was relatively modest and we had limited power to adjust for potential confounders or show correlations between the measured variables. Second, the diabetic patients were taking medications that might influence mitochondrial function and confound the results, although we observed no difference in oxygen consumption rates in diabetic patients who were or were not taking a statin, ACEI/ARB, or metformin. Finally, further studies will be needed to elucidate the mechanisms that account for the findings of this initial report.

In regard to the oxygen consumption methodology, several additional points are worth noting. First, the approach requires study of freshly isolated, live cells, which would make it less useful than a test that could be performed using frozen samples. Second, we used an XF96 Seahorse analyzer and had only two ports available for addition of oligomycin and FCCP to the well. As a result, we could not test the effects of antimycin A and rotenone to distinguish the contributions of proton leak and non-mitochondrial respiration to basal oxygen consumption. We did not have access to an XF24 analyzer, which has additional ports and might be used in future studies; however, the larger well size in that device would require a larger number of cells. These limitations are balanced by the potential utility of this method for clinical research and clinical care because it provides for the measurement of a key aspect of mitochondrial function in readily accessible PBMCs.

In summary, we described a method to evaluate oxygen consumption in freshly isolated PBMCs and used it to examine mitochondrial function in patients with diabetes mellitus. We observed higher basal, maximal, and uncoupled oxygen consumption in the diabetic patients, findings that are consistent with prior work showing increased mitochondrial ROS production in PBMCs. Oxygen consumption in circulating blood cells did not correlate with endothelial vasodilator function, although we did observe a correlation between nitroglycerin-mediated dilation and maximal oxygen consumption that may merit further study. These findings add to our understanding of mitochondrial dysfunction in circulating leukocytes that may be relevant to inflammation, immune dysfunction and cardiovascular disease in diabetes mellitus. Furthermore, our described method might be applied to epidemiological studies and intervention studies, and might eventually prove useful for clinical care.

Footnotes

Acknowledgements

We gratefully acknowledge Seahorse Bioscience, Inc. for the loan of an XF96 analyzer and donation of plates to conduct the described experiments. We also acknowledge the technical assistance of Mai-Anne Carey and Jonathan Aasen with the non-invasive testing of vascular function.

Declaration of conflicting interest

The authors declare that there is no conflict of interest.

Funding

The project was supported by NIH grants HL081587, HL083801, HL083269, and HL115391 from the National Heart, Lung, and Blood Institute. Drs Vita and Hamburg receive support from the NIH-sponsored Boston University Medical Center Leadership Program in Vascular Medicine (K12 HL083781). Dr Fetterman receives support from T32 HL007224. Dr Hamburg is supported by NIH grant HL102299.

References

Bailey

Landar

Darley-Usmar

. Mitochondrial proteomics in free radical research. Free Radic Biol Med 2005; 38: 175–188.

Ames

Shigenaga

Hagen

. Mitochondrial decay in aging. Biochim Biophys Acta 1995; 1271: 165–170.

Wallace

. A mitochondrial paradigm of metabolic and degenerative diseases, aging, and cancer: a dawn for evolutionary medicine. Annu Rev Genet 2005; 39: 359–407.

Swerdlow

. Mitochondrial medicine and the neurodegenerative mitochondriopathies. Pharmaceuticals (Basel) 2009; 2: 150–167.

Kluge

Fetterman

Vita

. Mitochondria and endothelial function. Circ Res 2013; 112: 1171–1188.

Brownlee

. Biochemistry and molecular cell biology of diabetic complications. Nature 2001; 414: 813–820.

Mootha

Lindgren

Eriksson

. PGC-1_α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 2003; 34: 267–273.

Lowell

Shulman

. Mitochondrial dysfunction and type 2 diabetes. Science 2005; 307: 384–387.

Shoelson

Lee

Goldfine

. Inflammation and insulin resistance. J Clin Invest 2006; 116: 1793–1801.

10.

Kim

Wei

Sowers

. Role of mitochondrial dysfunction in insulin resistance. Circ Res 2008; 102: 401–414.

11.

Patti

Corvera

. The role of mitochondria in the pathogenesis of type 2 diabetes. Endocr Rev 2010; 31: 364–395.

12.

Widlansky

Wang

Shenouda

. Altered mitochondrial membrane potential, mass, and morphology in the mononuclear cells of humans with type 2 diabetes. Transl Res 2010; 156: 15–25.

13.

Shenouda

Widlansky

Chen

. Altered mitochondrial dynamics contributes to endothelial dysfunction in diabetes mellitus. Circulation 2011; 124: 444–453.

14.

Kizhakekuttu

Wang

Dharmashankar

. Adverse alterations in mitochondrial function contribute to type 2 diabetes mellitus-related endothelial dysfunction in humans. Arterioscler Thromb Vasc Biol 2012; 32: 2531–2539.

15.

Tabit

Shenouda

Holbrook

. Protein kinase C-β contributes to impaired endothelial insulin signaling in humans with diabetes mellitus. Circulation 2013; 127: 86–95.

16.

Ferrick

Neilson

Beeson

. Advances in measuring cellular bioenergetics using extracellular flux. Drug Discov Today 2008; 13: 268–274.

17.

Dranka

Benavides

Diers

. Assessing bioenergetic function in response to oxidative stress by metabolic profiling. Free Radic Biol Med 2011; 51: 1621–1635.

18.

Perry

Kane

Lanza

Neufer

. Methods for assessing mitochondrial function in diabetes. Diabetes 2013; 62: 1041–1053.

19.

Graham

. Measurement of mitochondrial oxygen consumption using a Clark electrode. Methods Mol Biol 2012; 837: 63–72.

20.

Belikova

Lukaszewicz

Faivre

. Oxygen consumption of human peripheral blood mononuclear cells in severe human sepsis. Crit Care Med 2007; 35: 2702–2708.

21.

Kuhnke

Burmester

Krauss

Buttgereit

. Bioenergetics of immune cells to assess rheumatic disease activity and efficacy of glucocorticoid treatment. Ann Rheum Dis 2003; 62: 133–139.

22.

Tabit

Chung

Hamburg

Vita

. Endothelial dysfunction in diabetes mellitus: molecular mechanisms and clinical implications. Rev Endocr Metab Disord 2010; 11: 61–74.

23.

Grover

Marone

Koetzner

Seto-Young

. Energetic signalling in the control of mitochondrial F1F0 ATP synthase activity in health and disease. Int J Biochem Cell Biol 2008; 40: 2698–2701.

24.

McMackin

Vita

. Update on nitric oxide-dependent vasodilation in human subjects. Methods Enzymol 2005; 396: 541–553.

25.

Kipmen-Korgun

Bilmen-Sarikcioglu

Altunbas

Demir

Korgun

. Type-2 diabetes down-regulates glucose transporter proteins and genes of the human blood leukocytes. Scand J Clin Lab Invest 2009; 69: 350–358.

26.

Flammer

Anderson

Celermajer

. The assessment of endothelial function: from research into clinical practice. Circulation 2012; 126: 753–767.

27.

Mitchell

Parise

Vita

. Local shear stress and brachial artery flow-mediated dilation: The Framingham Heart Study. Hypertension 2004; 44: 134–139.

28.

Horan

Pichaud

Ballard

. Review: quantifying mitochondrial dysfunction in complex diseases of aging. J Gerontol A Biol Sci Med Sci 2012; 67: 1022–1035.

29.

Morino

Petersen

Dufour

. Reduced mitochondrial density and increased IRS-1 serine phosphorylation in muscle of insulin-resistant offspring of type 2 diabetic parents. J Clin Invest 2005; 115: 3587–3593.

30.

Petersen

Dufour

Shulman

. Decreased insulin-stimulated ATP synthesis and phosphate transport in muscle of insulin-resistant offspring of type 2 diabetic parents. PLoS Med 2005; 2: e233.

31.

Perl

Gergely

Jr Nagy

Koncz

Banki

. Mitochondrial hyperpolarization: a checkpoint of T-cell life, death and autoimmunity. Trends Immunol 2004; 25: 360–367.

32.

Emre

Hurtaud

Nubel

Criscuolo

Ricquier

Cassard-Doulcier

. Mitochondria contribute to LPS-induced MAPK activation via uncoupling protein UCP2 in macrophages. Biochem J 2007; 402: 271–278.

33.

Van der Windt

Everts

Chang

. Mitochondrial respiratory capacity is a critical regulator of CD8+ T cell memory development. Immunity 2012; 36: 68–78.

34.

Chacko

Kramer

Ravi

. Methods for defining distinct bioenergetic profiles in platelets, lymphocytes, monocytes, and neutrophils, and the oxidative burst from human blood. Lab Invest 2013; 93: 690–700.

35.

Hernandez-Mijares

Rocha

Apostolova

. Mitochondrial complex I impairment in leukocytes from type 2 diabetic patients. Free Radic Biol Med 2011; 50: 1215–1221.

36.

Avila

Huang

Stevens

. Platelet mitochondrial dysfunction is evident in type 2 diabetes in association with modifications of mitochondrial anti-oxidant stress proteins. Exp Clin Endocrinol Diabetes 2012; 120: 248–251.

37.

Petersen

Dufour

Befroy

Garcia

Shulman

. Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. N Engl J Med 2004; 350: 664–671.

38.

Bachschmid

Schildknecht

Matsui

. Vascular aging: chronic oxidative stress and impairment of redox signaling-consequences for vascular homeostasis and disease. Ann Med 2013; 45: 17–36.